Access to this symposium requires KEY ZONE access (paid
registration) to HDCN. For information about subscribing to HDCN,
please go to this link. |
|
Cell Injury and Recovery: How Do the Cell and Its Milieu Mediate Progressive Renal Disease? |
| |
|
|
wma |
mp3 |
|
Bissell M. |
Regulation of Cell Function by the Extracellular Matrix |
|
|
|
|
Weber K. |
Aldosterone and a Pro-Inflammatory/Vascular Phenotype |
|
|
|
|
|
Discussion |
|
|
|
|
Schnaper H. |
The Cytoskeleton Mediates Multiple Fibrogenic Signals |
|
|
|
|
|
Discussion |
|
|
|
|
Savill J. |
Apoptosis and Progression of Kidney Disease |
|
|
|
|
|
Discussion |
|
|
|
|
Developing Therapeutics for Progressive Renal Disease |
| |
|
|
wma |
mp3 |
|
Martin G. |
Partnerships between Academic and Industry |
|
|
|
|
|
Discussion |
|
|
|
|
Mauer M. |
Morphologic Analysis of Renal Tissue: What are Suitable Trial Endpoints? |
|
|
|
|
|
Discussion |
|
|
|
|
Klein J. |
Biomarkers in Plasma and Urine: What Type and Quality of Markers are Available for Fibrotic Disease? |
|
|
|
|
Throckmorton D. |
FDA Perspectives on Approval: What Endpoints are Acceptable? What is Required to Validate New Endpoints? |
|
|
|
|
|
Discussion |
|
|
|
|
Hostetter T. |
Trial Designs for Progressive Renal Disease: What are the Most Efficient Designs for Phase II and Phase III Studies? |
|
|
|
|
|
Discussion |
|
|
|
|
Kopp J. |
Animal and Human Trials of Antifibrotic Agents: What are Promising Therapeutic Agents Currently in Development? |
|
|
|
|
|
Discussion |
|
|
|
Visit us next week for new topics !
|
 |
Audio
tapes from this Symposia can be purchased from:
|
|
